AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
2018 · Cancer Discovery · 409 citations
https://doi.org/10.1158/2159-8290.cd-18-0387
G
Gordon Moody
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
75
Papers
1.7K
Citations
15
h-index
17
i10-index
Gordon Moody is an academic researcher from AstraZeneca (United States). The author has contributed to research in topics: CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers & Ovarian cancer diagnosis and treatment. The author has an h-index of 15, co-authored 64 publications.
Papers by this author
worksDiscovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere
2019 · Journal of Medicinal Chemistry · 24 citations
https://doi.org/10.1021/acs.jmedchem.9b01310
Data from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7565446
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat